The most accurate test for the widest patient population
- Accurate: Next-gen sequencing screen with 149 disease-causing mutations for superior detection across a diverse patient population, with the option to increase the panel to 600 mutations for greater coverage of rare mutations
- Flexible: Blood, buccal swab, or mouthwash specimens accepted
- Affordable: With patient-friendly billing and Progenity's Peace of Mind program
About Cystic Fibrosis
Cystic fibrosis (CF) is the most common life-threatening genetic disease in North America. There are 10 million symptomless carriers of this chronic disease. CF patients have an average lifespan of 37 years.
Cystic fibrosis is a progressive, multisystem disease that primarily affects the pulmonary, pancreatic, and gastrointestinal systems, but does not affect intelligence. The current average lifespan is approximately 37 years, with respiratory failure as the most common cause of death. More than 95% of males with CF have congenital bilateral absence of the vas deferens (CBAVD), leading to infertility.
CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF is an autosomal recessive disorder. When both parents are carriers, there is a 1 in 4, or 25%, chance the pregnancy will be affected.
Superior Detection Rates Across All Ethnic Groups
The American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG) recommends that all women of reproductive age should be offered CF carrier screening, regardless of race or ethnicity. “It is becoming increasingly difficult to assign a single ethnicity to individuals. It is reasonable, therefore, to offer CF carrier screening to all patients.”1 CFnxt has been carefully designed to provide the most accurate results across a diverse patient population.
Reduced Residual Risk Across All Ethnic Groups
A negative screening test result reduces, but does not eliminate, the chance of being a CF carrier and having affected offspring. A patient who receives a negative test result still has a residual risk of being a carrier. Residual risk is reduced with the CFnxt test compared to other available tests.
All women of childbearing age should be offered screening for CF, regardless of race or ethnicity.1
The trend toward preconception carrier screening
For couples who are carriers of a genetic disorder, learning about their carrier status during a pregnancy is less than ideal. Women who are aware of their carrier status prior to conception have additional reproductive options for preventing the genetic disease.
According to ACOG, “preconception carrier screening allows couples to consider the most complete range of reproductive options. Knowledge of the risk of having an affected child may influence a couple’s decision to conceive or to consider preimplantation genetic diagnosis, prenatal genetic testing, or the use of donor gametes.”1
Offering carrier screening during the annual wellness visit allows patients to make informed reproductive choices.